New Delhi [India], September 24 (ANI): The Union Health Ministry on Friday hinted that World Health Organizationās emergency use authorization to Covaxin is expected soon.
However, the World Health Organisationās (WHO) approval for the emergency use authorisation (EUA) to Covid-19 vaccine, Covaxin, is likely to be delayed as per international public health agency. In this regard, the Strategic Advisory Group of Expert on Immunization (SAGE) will be meeting on October 5 to grant EUA to Covaxin.
āThere is a procedure of submitting the documents for approval. WHOās emergency use authorization to Covaxin is expected soon,ā said Dr Bharati Pravin Pawar who is currently the Union Minister of State in the Health Ministry.
According to Bharat Biotech, Phase-3 clinical trials of Covaxin demonstrated an efficacy rate of 77.8 per cent.
All the relevant trial data has been submitted to WHO for Emergency Use Listing (EUL) and all clarifications by the UN health agency have been responded to Bharat Biotech.
āWe have responded to clarifications sought by WHO and are awaiting further feedback. As a responsible manufacturer with several prequalified vaccines, we do not find it appropriate to speculate or comment on the approval process and its timelines,ā the Hyderabad based company said in a statement.
Earlier speaking to ANI, Chairperson of National Expert Group on Vaccine Administration and Member of Health for NITI Aayog, Dr VK Paul said that the WHOās approval for Bharat Biotechās COVID-19 vaccine, Covaxin is likely to come before the end of this month.
The WHO has approved COVID-19 vaccines by Pfizer-BioNTech, AstraZeneca, Johnson and Johnson, Moderna and Sinopharm till date.
As of date, India is using three vaccines against COVID-19 in its immunization drive. These include two made-in-India vaccines ā Serum Institute of Indiaās Covishield and Bharat Biotechās Covaxin. The Russian Sputnik V is the third vaccine that got approval from the Drug Controller General of India (DCGI) for Emergency Use Authorisation.
In Phase I of the vaccination drive, started on January 16, the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC) prioritised Health Care Workers and Front Line Workers (both government and private sector).
Phase II of the vaccination drive started from March 1 2021, focused on protecting the most vulnerable age groups. These prioritised age-groups included persons above 60 years of age and persons above 45 years with associated specified co-morbidities.
This was further relaxed to all people above 45 years of age on April 1, 2021. In Phase III, āLiberalised Pricing and Accelerated National COVID-19 Vaccination Strategyā was adopted on May 1, 2021. Under this strategy, everyone above 18 years of age are eligible for COVID-19 vaccination. (ANI)
About The Author
